JP2017502016A - １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置 - Google Patents

１型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置 Download PDF

Info

Publication number
JP2017502016A
JP2017502016A JP2016540574A JP2016540574A JP2017502016A JP 2017502016 A JP2017502016 A JP 2017502016A JP 2016540574 A JP2016540574 A JP 2016540574A JP 2016540574 A JP2016540574 A JP 2016540574A JP 2017502016 A JP2017502016 A JP 2017502016A
Authority
JP
Japan
Prior art keywords
combination
inhibitor
cancer
delta
cas number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016540574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502016A5 (enrdf_load_stackoverflow
Inventor
サウラブ サハ，
サウラブ サハ，
ゲイリー デクレッセンゾ，
ゲイリー デクレッセンゾ，
ジェフリー ジェイムズ ロワ，
ジェフリー ジェイムズ ロワ，
Original Assignee
バイオメッド バレー ディスカバリーズ，インコーポレイティド
バイオメッド バレー ディスカバリーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオメッド バレー ディスカバリーズ，インコーポレイティド, バイオメッド バレー ディスカバリーズ，インコーポレイティド filed Critical バイオメッド バレー ディスカバリーズ，インコーポレイティド
Publication of JP2017502016A publication Critical patent/JP2017502016A/ja
Publication of JP2017502016A5 publication Critical patent/JP2017502016A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016540574A 2013-12-20 2014-12-19 １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置 Pending JP2017502016A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919606P 2013-12-20 2013-12-20
US61/919,606 2013-12-20
PCT/US2014/071744 WO2015095838A2 (en) 2013-12-20 2014-12-19 Cancer treatments using combinations of mek type i and erk inhibitors

Publications (2)

Publication Number Publication Date
JP2017502016A true JP2017502016A (ja) 2017-01-19
JP2017502016A5 JP2017502016A5 (enrdf_load_stackoverflow) 2018-02-01

Family

ID=53403902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540574A Pending JP2017502016A (ja) 2013-12-20 2014-12-19 １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置

Country Status (5)

Country Link
US (1) US20160310477A1 (enrdf_load_stackoverflow)
EP (1) EP3082422A4 (enrdf_load_stackoverflow)
JP (1) JP2017502016A (enrdf_load_stackoverflow)
AU (1) AU2014368925A1 (enrdf_load_stackoverflow)
WO (1) WO2015095838A2 (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088986A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
MX2019013634A (es) * 2017-05-16 2020-01-21 Biomed Valley Discoveries Inc Composiciones y metodos para tratar cancer con mutaciones de braf atipicas.
CN112402413B (zh) * 2020-11-26 2022-03-08 重庆三峡医药高等专科学校 野马追倍半萜内酯b在制备抗肝癌药物中的应用及一种抗肝癌药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519142A (ja) * 1999-12-24 2003-06-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ベンザゾール誘導体と、そのｊｎｋモジュレータとしての利用法
JP2007537295A (ja) * 2004-05-14 2007-12-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体
JP2008514635A (ja) * 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
JP2010529122A (ja) * 2007-06-05 2010-08-26 シェーリング コーポレイション 多環式インダゾール誘導体および癌の治療のためのｅｒｋ阻害剤としてのそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003248813A1 (en) * 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2008067069A2 (en) * 2006-10-19 2008-06-05 Oregon Health & Science University Mitogen activated protein kinase phosphatase 4 (mkp4) and methods of use thereof
AU2010217606C1 (en) * 2009-02-26 2017-01-19 Boehringer Ingelheim International Gmbh Compounds as bradykinin B1 antagonists
US20130053434A1 (en) * 2009-09-28 2013-02-28 Centre National De La Recherche Scientifique Irreversible inhibitors useful for the treatment of kinase-related pathologies
DK2624696T3 (en) * 2010-10-06 2017-03-13 Glaxosmithkline Llc Corp Service Company BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519142A (ja) * 1999-12-24 2003-06-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ベンザゾール誘導体と、そのｊｎｋモジュレータとしての利用法
JP2007537295A (ja) * 2004-05-14 2007-12-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体
JP2008514635A (ja) * 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
JP2010529122A (ja) * 2007-06-05 2010-08-26 シェーリング コーポレイション 多環式インダゾール誘導体および癌の治療のためのｅｒｋ阻害剤としてのそれらの使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEMISTRY, 1998, VOL.37, P.9579-9585, JPN6018039355, ISSN: 0004067598 *
CANCER DISCOVERY, 2013/7,VOL.3(7), P.742-750, JPN6018039350, ISSN: 0004067596 *
GEORGIA HATZIVASSILIOU: "ERK INHIBITION OVERCOMES ACQUIRED RESISTANCE TO MEK INHIBITORS", MOLECULAR CANCER THERAPEUTICS, vol. V11 N5, JPN5016013048, May 2012 (2012-05-01), pages 1143 - 1154, ISSN: 0004067595 *
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2009, VOL.22(4), P.889-895, JPN6018039353, ISSN: 0004067597 *

Also Published As

Publication number Publication date
WO2015095838A3 (en) 2015-11-12
WO2015095838A2 (en) 2015-06-25
AU2014368925A1 (en) 2016-07-21
US20160310477A1 (en) 2016-10-27
EP3082422A2 (en) 2016-10-26
EP3082422A4 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
US12076324B2 (en) Cancer treatments using combinations of CDK and ERK inhibitors
JP6727127B2 (ja) Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
CA2934669C (en) Cancer treatment using combinations of erk and raf inhibitors
JP2017502016A (ja) １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置
JP2022034068A (ja) 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
ES2986019T3 (es) Tratamientos contra el cáncer que usan combinaciones de inhibidores de ERK y MEK de tipo 2
WO2015095807A1 (en) Cancer treatments using combinations of egfr and erk inhibitors
HK1226252B (en) Cancer treatments using combinations of cdk and erk inhibitors
HK1226252A1 (en) Cancer treatments using combinations of cdk and erk inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181219

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190109

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190702